Performance of an infliximab precision-guided dosing tool from a capillary blood–based self-collection device in inflammatory bowel disease patients
Inflammatory Bowel Diseases · 2026-11-05
DOI: 10.1093/ibd/izag214 ↗Abstract
Abstract Background and Aims Infliximab (IFX) trough concentrations are routinely measured to guide dosing and optimize efficacy. Bayesian forecasting tools may enable earlier prediction of trough concentrations, while patient-friendly capillary self-collection devices could improve access to precision-guided dosing (PGD). We evaluated the performance of the PredictrPK IFX platform in forecasting IFX trough concentrations by using serum collected with an upper-arm self-collection device and compared its performance with standard venous blood obtained by phlebotomy. Methods Patients with inflammatory bowel disease (IBD) receiving IFX maintenance therapy were recruited from a single IBD center. Midcycle samples collected via an upper-arm self-collection device and via traditional venipuncture were compared. The IFX clearance was estimated by use of a nonlinear mixed-effects model with Bayesian priors and the predicted IFX levels were compared with measured trough concentrations obtained prior to infusions. Deming regression was used for statistical analysis. Results The study included 57 patients (61% males, median age, 34 years). The median IFX dose was 10 mg/kg with a median interdose interval of 6 weeks. A total of 97 capillary and venous blood pairs were tested. Concentrations of IFX from venous and capillary blood samples demonstrated strong correlations (R2 = 0.987, Demings = 1.08). There was also a strong association between predicted IFX concentrations and measured IFX trough concentrations. Conclusion PredictrPK accurately predicted IFX trough concentrations. Capillary self-collection using an upper-arm device yielded results comparable to those from venous blood measurement, which may facilitate increased implementation and accessibility of PGD in clinical practice.
EUVIMED